Calcium and phosphorus metabolism in nephrotic syndrome.
Calcium and phosphorus balance studies were performed on 13 nephrotic patients and eight patients during clinical remission of the nephrotic syndrome. Marked impairment of intestinal absorption of calcium was found among nephrotic patients, in eight of whom faecal calcium equalled or exceeded dietary calcium. The mean faecal:dietary calcium ratio of nephrotic patients, 1-06 +/- 0-23 (SD), was significantly higher (p less than 0-005) than that of patients in remission, 0-58 +/- 0-21 (SD). The mean 24-hour urinary excretion of calcium of nephrotic patients, 0-68 +/- 0-68 (SD) mmol, was significantly lower (p less than 0-005) than that of patients in remission, 3-02 +/- 1-91 (SD) mmol. Calciferol administered to three nephrotic patients in the dosage of 1.25 mg per day did not significantly influence intestinal absorption or renal excretion of calcium. There was no difference between the two groups of patients in intestinal absorption or renal excretion of phosphorus; there was net intestinal absorption in all subjects. Quantitative bone histology was studied in seven of the nephrotic patients. None had osteomalacia or osteitis fibrosa, while only one had evidence of mild osteoporosis.
D000293:Adolescent; D000328:Adult; D001842:Bone and Bones / Q000473:pathology; D002118:Calcium / Q000378:metabolism*; D004872:Ergocalciferols / Q000494:pharmacology; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D008286:Malabsorption Syndromes / Q000378:metabolism; D008297:Male; D009404:Nephrotic Syndrome / Q000378:metabolism* / Q000473:pathology; D010758:Phosphorus / Q000378:metabolism*
D004872:Ergocalciferols; D010758:Phosphorus; D002118:Calcium